This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab.
Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT.
Among 160 patients from 24 U.S. centers enrolled in the study (103 [64%] ≥75 years of age), 84.7% on average complied with daily mVT testing and ∼98.9% complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders.
Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.
Supplemental Digital Content is Available in the Text.This pilot study tested the feasibility of a novel remote daily monitoring system for patients with neovascular age-related macular degeneration treated with ranibizumab. In this study, the system worked as expected, and compliance with daily visual function testing on mobile handheld devices averaged 84.7% among the 160 elderly patients enrolled.
*Cole Eye Institute, Cleveland, Ohio;
†Retina Foundation of the Southwest, Dallas, Texas;
‡Department of Ophthalmology, UT Southwestern Medical Center, Dallas, Texas;
§Novartis Pharmaceuticals Corp, East Hanover, New Jersey;
¶Novartis Pharma AG, Basel, Switzerland; and
**Aegis Creative Communications, Inc, Lakewood, Colorado.
Reprint requests: Peter K. Kaiser, MD, Cole Eye Institute, Cleveland Clinic Main Campus, Mail Code i32, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: email@example.com
Supported by Novartis Pharma AG.
P. K. Kaiser is a consultant for Novartis and Genentech. Y.-Z. Wang and Y.-G. He are consultants for and cofounders of Vital Art and Science, Inc, which developed myVisionTrack (mVT). A. Weisberger is an employee of Novartis Pharmaceuticals Corporation and owns Novartis stock. S. Wolf is an employee of Novartis Pharma AG, Switzerland. C. H. Smith was an employee of Novartis during the clinical study, is a member of the board of Vital Art and Science, Inc, and is currently an employee of Aegis Creative Communications, Inc, which developed the Health Management Tool (HMT).
The authors declare no conflict of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.retinajournal.com).